Developing the future of CAR-T cell therapy today

Novartis is pioneering the way in the class of cell and gene treatment and has developed the first CAR-T cell therapy approved for paediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (ALL). This heritage includes setting the standard in patient and caregiver support, safety and efficacy, access, and partnerships with healthcare institutions, local health authorities, and academic institutions around the world.

Grandmother tying her grandson's shoe laces

Patients and Caregivers

This page includes information for patients and caregivers about CAR-T cell therapy, the treatment process, who can benefit from this therapy, and what makes CAR-T cell therapy different from other treatment options.

Image of two healthcare professionals interacting

Healthcare Professionals

This page includes information for healthcare professionals about the science, process, landscape, and pioneers of CAR-T cell therapy.

Icon of telescope
Icon of electric lightbulb
Icon of stamp with a heart
Icon of eye

Expanding horizons

Innovating immunotherapy

Delivering hope

Focusing on patients

CAR-T cell therapy is a one-time treatment after which patients may not need another therapy, aiming to deliver long-term value and hope to patients and society.

One of the first personalised treatments in the age of precision medicine, CAR-T cell therapy enhances the strength of a patient’s existing T cells to target B-cell malignancies.

For relapsed or refractory patients, CAR-T cell therapy offers a different treatment option with the hope of long-term efficacy, along with a manageable safety profile.

The patient is at the center of the process for CAR-T cell therapy. The process begins with the patient at autologous T-cell collection and ends with the patient at infusion.


We need to reimagine medicine, because the world and patients need us to.

Vas Narasimhan, CEO of Novartis


  1. Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) [press release]. Basel, Switzerland. Novartis Pharma AG; August 27, 2018.
  2. Kymriah Summary of Product Characteristics. Novartis Pharma AG; 2018.
  3. Novartis. Novartis Annual Review. Novartis Pharma AG. Accessed April 22, 2019. Novartis Annual Review 2018 (PDF 12.4 MB).